

# Synthesis and biological activities of $2\alpha$ -chloro-1-epicalcitriol and 1-epicalcitriol

# Bruno Schönecker,\* Manfred Reichenbächer,\* Sabine Gliesing,\* Manuela Gonschior,\* Sirid Griebenow,\* Dietmar Scheddin,† and Hubert Mayer†

\* Department of Chemistry, The Friedrich Schiller University Jena, Jena, Germany; and † Department of Gene Regulation and Differentiation, Association for Biotechnological Research, Braunschweig, Germany

Anomalous diequatorial epoxide ring opening of  $1\beta,2\beta$ -oxido-cholesta-5,7-diene- $3\beta,25$ -diol 1 produces the  $1\beta$ -hydroxy- $2\alpha$ -chloro-provitamin 2 and its corresponding  $1\beta$ -hydroxy-provitamin 3. The provitamins 2 and 3 are transformed by irradiation and thermal isomerization to  $2\alpha$ -chloro-1-epicalcitriol NS3 (4) and 1-epicalcitriol NS8 (5), respectively. These two A-ring derivatives were tested for their in vitro biological activity in the mesenchymal, murine cell line C3H10T<sup>1</sup>/<sub>2</sub>, and their effects were compared with those of the native vitamin  $D_3$  derivatives  $25(OH)D_3$  and  $1,25(OH)_2D_3$ . NS3 and NS8 showed marked differences in their affinity for the vitamin D binding protein (DBP) and in their ability to inhibit cell proliferation. NS8 has the ability to bind to a high-affinity DBP-binding site for which  $25(OH)D_3$  has none affinity. The  $2\alpha$ -chloro-substitution (NS3) prevents binding to the postulated noncompetitive, NS8-specific DBP-binding site and diminishes the affinity to the vitamin D receptor (VDR) and therefore diminishing NS3's biological abilities. The elucidation of the structure-function relationships at the DBP-binding-sites could have major impact on the development of new vitamin  $D_3$  derivatives with extended serum half-life. (Steroids 63:28–36, 1998) © 1998 by Elsevier Science Inc.

**Keywords:** vitamin D; A-ring derivatives; diequatorial  $1\beta$ ,  $2\beta$ -epoxide cleavage; vitamin D responsive element; vitamin D binding protein; affinity studies

# Introduction

The biologically active vitamin  $D_3$  metabolite,  $1,25(OH)_2D_3$ is of pivotal importance in mediating calcium and phosphorous homeostasis as well as in controlling the differentiation and proliferation of several cell types.<sup>1–4</sup> This has augmented the efforts to develop vitamin  $D_3$  derivatives with highly specific effects in contrast to the pluripotent activity of  $1,25(OH)_2D_3$ . The interest is centered on the development of vitamin  $D_3$  derivatives with low calcemic activity and with the ability to inhibit proliferation and to modulate differentiation.<sup>5–7</sup> Most of these substances were side chain derivatives of  $1,25(OH)_2D_3$  with unchanged A-ring structure and configuration. In this study, we report the synthesis and the biological capabilities of 1-epicalcitriol and  $2\alpha$ chloro-1-epicalcitriol, both derived from  $1\beta,2\beta$ -oxidocholesta-5,7-dien-3 $\beta$ ,25-diol **1**. The  $1\beta$ -hydroxy derivative

Dedicated to Prof. Dr. P. Welzel on the occasion of his 60th birthday.

**NS8** (1-epicalcitriol) has been previously characterized as a potent antagonist of  $1,25(OH)_2D_3$ -induced intestinal calcium transport (transcaltachia).<sup>8</sup>  $2\alpha$ -Chloro-1-epicalcitriol (**NS3**) is a new derivative and to our knowledge the first member of the  $2\alpha$ -substituted 1-epicalcitriols. Recently,  $2\beta$ -substituted 1-epicalcitriols with interesting biological activities have been described.<sup>9</sup>

For the cell culture experiments, we used the murine fibroblastic cell line C3H10T<sup>1</sup>/2. After stable transfection with the human bone morphogenetic-4 (BMP-4) gene, this cell line has the ability to differentiate into chondrocytes, adipocytes, and cells of the osteogenic lineage by addition of ascorbate and  $\beta$ -glycerophosphate.<sup>10</sup> It is possible to cultivate this cell line for up to four weeks in the absence of fetal calf serum (FCS) so that the in vitro cellular effects of vitamin D<sub>3</sub> derivatives can be separated from their DBPmediated actions (FCS contains significant amounts of DBP). We used this highly vitamin D-sensitive cell line to test the ability of vitamin D<sub>3</sub> derivatives to inhibit cell proliferation and modulate adipocyte differentiation.11 C3H10T<sup>1</sup>/<sub>2</sub>-cells were also stably transfected with a construct containing the vitamin D responsive element (VDRE) of the human osteocalcin gene coupled to a chloramphenicolacetyltransferase (CAT)-reporter gene in order to evalu-

Address reprint requests to Bruno Schönecker, Institute of Organic and Macromolecular Chemistry, The Friedrich Schiller University Jena, Humboldtstra $\beta$ e 10, D-07743 Jena, Germany, or Hubert Mayer, Department of Gene Regulation and Differentiation, Association for Biotechnological Research, Mascheroder Weg 1, D-38124 Braunschweig, Germany. Received April 28, 1997; accepted September 10, 1997.

ate the ability of the vitamin  $D_3$  derivatives to activate gene transcription at the VDRE.

# **Experimental**

## Chemistry

1β,2β-oxido-cholesta-5,7-dien-3β,25-diol **1** was synthesized from (20S)-20-(*p*-toluene-sulfonyloxymethyl)-pregna-1,5-dien-3β-ol<sup>12</sup> in 8 steps, as previously described.<sup>13,14</sup> The 1β,2β-epoxy group of compound **1** reacts with hydrochloric acid in *N*,*N*-dimethyl-formamide via an anomalous trans-diequatorial intermediate, giving the 1β-hydroxy-2α-chloro compound **2** (<sup>1</sup>H NMR data). By reductive cleavage of the 1β,2β-epoxy group of **1** with lithium aluminum hydride, the hitherto unknown 1β-hydroxy compound **3** (provitamin of 1-epicalcitriol) was formed, in contrast to the 2β-hydroxy compound we previously specified.<sup>13</sup>

For the transformation of the provitamins into the previtamins, simultaneous irradiation at  $<-40^{\circ}$ C with light in the range of 285 to 300 nm and >330 nm was carried out (filter solution), as described for the synthesis of precalcitriol.<sup>15</sup> Irradiation was terminated after nearly 50% of the provitamins was consumed in order to avoid the production of undesired side products. HPLC and flash chromatography<sup>16</sup> furnished the desired previtamins, starting materials, and mixtures of the other photoisomers. The starting materials (provitamins) and the other photoisomers were recycled to improve the yields of previtamins.<sup>15</sup>

After chromatographic purification, thermal isomerization of the previtamins gave vitamins **NS3** and **NS8**. The lower yields in comparison to the synthesis of calcitriol<sup>15</sup> are due to the lack of optimized reaction conditions (irradiation and isomerization). In this way, 1-epicalcitriol (**NS8**) was synthesized for the first time by UV irradiation and thermal isomerization.

The trans-diequatorial epoxide opening of compound **1** is surprising. Normally,  $1\beta$ , $2\beta$ -epoxides with a saturated A-ring give the trans-diaxial  $1\alpha$ -substituted  $2\beta$ -hydroxy compounds.<sup>17–19</sup> The reasons for the anomalous epoxide cleavage of compound **1**, which has an unsaturated B-ring, are under investigation. Through this anomalous cleavage, a route was developed to the production of a new class of provitamins and vitamins possessing a  $1\beta$ -hydroxy group and a substituent in the  $2\alpha$ -position.

# General remarks

Solvents were distilled and dried before use according to conventional methods. N,N-Dimethyl formamide was dried over molecular sieves 4Å and distilled in vacuo. All reactions were conducted under an atmosphere of dry argon and under exclusion of UV light. TLC: silicagel 60 F254 (MERCK) plates, layer thickness 0.2 mm, detection by UV ( $\lambda_1 = 254$  nm;  $\lambda_2 = 366$  nm) and spraying with a solution consisting of 80 mL conc. sulfuric acid and 20 mL methanol and by heating at 120°C. Flash column chromatography:<sup>16</sup> LiChroprep (MERCK, 25-40 µm) [eluents (v/v) are given in parentheses]. HPLC: SHIMADZU LC-8A equipped with a UV/VIS spectrophotometric detector SPD-10AV, stationary phases: LiChrosorb DIOL (MERCK,  $150 \times 3$  mm,  $5 \mu$ m) or LiChrosorb DIOL (MERCK, 250  $\times$  25 mm, 7  $\mu$ m) [eluents (v/v) are given in parentheses]. Melting points: Boetius micromelting point apparatus, uncorrected values. High-resolution mass spectra (HRMS): AMD 402 intectra with electron impact ionization at 70 eV. Nuclear magnetic resonance (NMR) spectra: BRUKER DRX 400 [chemical shifts ( $\delta$ ) are reported in ppm, relative to tetramethylsilane as the internal standard] Signals are assigned by TOCSY, selective TOCSY. UV spectra: CARL ZEISS JENA Specord M 500 [extinction coefficients ( $\epsilon$ ) are given in 1 mol<sup>-1</sup>  $cm^{-1}$  in parentheses].

#### $2\alpha$ -Chloro-cholesta-5,7-dien-1 $\beta$ ,3 $\beta$ ,25-triol 2

Epoxide 1 (1.25 g; 3.1 mmol) was dissolved in N,N-dimethyl formamide (80 mL) in absence of UV light. Conc. hydrochloric acid (3.3 mL; 4.2 mmol) in N,N-dimethyl formamide (20 mL) was added while stirring after 1 to 2 h, (TLC: ethyl acetate/isohexane 40/60 v/v) the reaction mixture was poured into chilled water. The mixture was extracted with diethyl ether, and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation in vacuo, a white solid (1.23 g) was obtained, which was recrystallized from ethyl acetate/ isohexane (75/25 v/v) giving white crystals of 2 (0.92 g). Flash chromatography of the mother liquor further gave crystalline 2 (0.13 g). Yield: 1.05 g (76%). m.p. 198-203°C. UV (CH<sub>3</sub>OH)  $\lambda_{\text{max}} = 284 \text{ nm} (\epsilon = 11300).$  <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 0.63 (s, 3H, 18-H); 0.97 (d,  ${}^{3}J = 6.5$ Hz, 3H, 21-H); 1.10 (s, 3H, 19-H); 1.23 (s, 6H, 26-H and 27-H); 3.62 (m, 2H, 1 $\alpha$ -H and 3 $\alpha$ -H); 3.96 (t, J = 9.9Hz, 1H, 2 $\beta$ -H); 5.33 (d,  ${}^{3}J = 5.9$ Hz, 1H, 7-H); 5.68 (dd,  ${}^{3}J = 5.8$ Hz, 1H, 6-H). Addition of trichloroacetyl isocyanate:  $\delta$ : 1.60 (s, 6H, 26-H and 27-H); 4.27 (t,  ${}^{3}J = 10.5$ Hz, 1H, 2 $\beta$ -H); 4.90 (m, 1H,  $3\alpha$ -H); 5.25 (d,  ${}^{3}J = 10.4$ Hz, 1H,  $1\alpha$ -H); 8.18 (s, 1H, NH); 8.37 (s, 2H, NH). HRMS m/z found 450.2921 (calculated for C<sub>27</sub>H<sub>43</sub>O<sub>3</sub>Cl: 450.2889)

#### (5Z,7E)-9,10-Seco-2α-chloro-cholesta-5,7,10(19)trien-1β,3β,25-triol **NS3** 4

 $2\alpha$ -Chloro-provitamin 2 (150 mg; 0.33 mmol) was dissolved in CH<sub>2</sub>OH (100 mL) and *tert*-butyl methyl ether (350 mL), transferred to a photoreactor, and flushed with argon for 45 min. After cooling to  $-40^{\circ}$ C, irradiation was carried out using a filter solution of 2,7-dimethyl-3,6-diaza-cyclohepta-1,6-diene tetrafluoroborate and biphenyl in ethanol and a high pressure mercury lamp TQ 150 Z1. After 140 min, the irradiation was stopped (HPLC control: LiChrospher DIOL, i-propanol/i-hexane (8/92 v/v, detection  $\lambda_1$  = 260 nm,  $\lambda_2 = 280$  nm), and the solvents were evaporated in vacuo. The residue was dissolved in ethyl acetate/i-hexane (20 mL, 70/30 v/v) and crystallized at  $-18^{\circ}C$  (12 h). Unreacted provitamin 2 (55 mg; 37%) was obtained. The mother liqour was evaporated in vacuo, the residue was dissolved in i-propanol/i-hexane (5 mL, 10/90 v/v) and separated by HPLC (LiChrospher DIOL 7  $\mu$ m  $250 \times 25$  mm, i-propanol/i-hexane 8/92 v/v, 15 mL/min detection  $\lambda_1 = 260$  nm,  $\lambda_2 = 280$  nm) to give the expected previtamin (20 mg, 13%) as a colorless foam, further starting provitamin 2 (15 mg, 10%), and a mixture of 2 and other photoproducts (30 mg, 20%). After recycling of 2, a total amount of 29 mg (19%) previtamin was obtained.

This previtamin (UV  $\lambda_{max}$  = 259 nm) was immediately dissolved in i-propanol/i-hexane (10 mL, 10/90 v/v) in the dark under argon and heated to 40 to 50°C for 5 h (HPLC control: LiChrospher DIOL, i-propanol/i-hexane 8/92 v/v, detection  $\lambda$  = 260 nm). The solution was evaporated in vacuo, the residue was dissolved in i-propanol/i-hexane (2 mL, 10/90 v/v) and separated by HPLC (LiChrosorb DIOL 7  $\mu$ m 250  $\times$  25 mm, i-propanol/ihexane 10/90 v/v, 17 mL/min, detection  $\lambda_1 = 260$  nm,  $\lambda_2 = 230$ nm). After evaporation and drying in vacuo, the following products were obtained: 1.) 15 mg previtamin (53%) 2.) 9 mg 2 $\alpha$ chlorovitamin 4 (31%). The unreacted previtamin was thermically isomerized once more giving additional vitamin 4 as white needles. m.p. 173–179°C (CH<sub>3</sub>OH). UV (CH<sub>3</sub>OH)  $\lambda_{max} = 264$  nm ( $\epsilon = 15300$ ). <sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>)  $\delta$ : 0.50 (s, 3H, 18-H); 0.91 (d,  ${}^{3}J = 6.3$ Hz, 3H, 21-H); 1.19 (s, 6H, 26-H and 27-H); 2.25 (m, 1H, 4 $\beta$ -H); 2.54 (t,  ${}^{3}J = 9.7$ Hz, 4 $\alpha$ -H); 2.71 (m, 1H, 9 $\beta$ -H); 3.81–3.83 (m, 2H, 2β-H and 3α-H); 4.12 (m, 1H, 1α-H); 5.11 and 5.56 (2 × t,  ${}^{4}J$  = 2Hz, 2H, 19-H); 5.94 and 6.38 (2 × d,  ${}^{3}J$  = 11,3Hz, 2H, 7- and 6-H). Addition of trichloroacetyl isocyanate: δ: 1.49 (s, 6H, 26-H and 27-H); 4.13 (t,  ${}^{3}J = 7.1$ Hz, 1H, 2 $\beta$ -H); 5.22 (m, 1H,  $3\alpha$ -H); 5.51 (d,  ${}^{3}J = 7.3$ Hz 1H,  $1\alpha$ -H); 8.17 (s, 1H, NH);



Scheme

Scheme a: HCI/DMF, r.t.; b: i photoisomerization: tert-butyl methyl ether/ CH<sub>3</sub>OH (80/20 v/v); photoreactor, Hg high pressure lamp (TQ 150 Z1), filter solution (2,7-dimethyl-3,6-diaza-cyclohepta-1,6diene-tetrafluoroborate/biphenyl), 140 min; *ii* HPLC: diol gel 7 μm, propan-2-ol/i-hexane (8/92 v/v); iii thermal isomerization: propan-2-ol/i-hexane (10/90 v/v); 40-50°C, 5 h; iv HPLC: diol gel 7 µm, propan-2-ol/i-hexane (10/90 v/v); c: LiAIH<sub>4</sub>/ether, r.t.; d: i photoisomerization: tert-butyl methyl ether/ CH<sub>3</sub>OH (90/10 v/v); photoreactor, Hg high pressure lamp (TQ 150 Z1), filter solution (2,7-dimethyl-3,6-diaza-cyclohepta-1,6diene-tetrafluoroborate/biphenyl), 45 min; ii flash chromatography: Ag<sup>+</sup>-modified silica gel 25-40 µm, ethyl acetate/hexane (70/30 v/v); iii thermal isomerization: ethyl acetate/ hexane (75/25 v/v); 55-60°C, 5 h; iv flash chromatography: Ag<sup>+</sup>-modified silica gel 25-40  $\mu$ m, ethyl acetate/hexane (75/25 v/v).

8.58 (s, 2H, NH). HRMS m/z found 450.2917 (calculated for  $\rm C_{27}H_{43}O_3Cl;$  450.2889).

#### 1β,3β,25-Trihydroxy-cholesta-5,7-dien 3

Epoxide 1 (250 mg; 0.6 mmol) was dissolved in THF (20 mL). A solution of LiAIH<sub>4</sub> (76 mg; 2 mmol) in THF (25 mL) was added at 0°C with stirring, and the mixture was refluxed (about 30 min) until starting material was no longer detectable by TLC (TLC: ethyl acetate/hexane 75/25 v/v; R<sub>f</sub>: 1: 0.45; 3: 0.28). Diethylether (100 mL) was added, and the reaction mixture was poured into chilled water. The organic layer was separated, and the A1(OH)<sub>3</sub> residue was extracted several times with methanol (50 mL). The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under reduced pressure. The yellowish crude product was recrystallized from methanol giving white needles of 3 (165 mg, 65.7%), and the mother liquor was purified by flash chromatography (ethyl acetate/hexane 75/25 v/v) giving more 3 (48 mg, 19.1%). UV (CH<sub>3</sub>OH)  $\lambda_{\text{max}} = 284$  nm ( $\epsilon = 11400$ ). <sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>)  $\delta$ : 0.61 (s, 3H, 18-H); 0.94 (d, <sup>3</sup>J  $\approx$  6.3Hz, 3H, 21-H); 1.03 (s, 3H, 19-H); 1.22 (s, 6H, 26-H and 27-H); 3.70 (m, 2H, 1 $\alpha$ -H and 3 $\alpha$ -H); 5.25 (m, 1H, 7-H); 5.64 (dd,  ${}^{3}J \approx 6.5$ Hz,  ${}^{4}J \approx 1.5$ Hz, 1H, 6-H). Addition of trichloroacetyl isocyanate:  $\delta$ : 0.60 (s, 3H, 18-H); 0.92 (d,  ${}^{3}J \approx 6.1$  Hz, 3H, 21-H); 1.16 (s, 3H, 19-H); 1.53 (s, 6H, 26-H and 27-H); 5.39 (dd,  ${}^{3}J \approx 6.5$ Hz,  ${}^{4}J \approx$ 1.5Hz, 1H, 7-H); 5.73 (m, 1H, 6-H); 8.20, 8.34 and 8.40 (3  $\times$  s,  $3 \times 1H$ ,  $3 \times NH$ ) HRMS m/z found 416.3279 (calculated for C<sub>27</sub>H<sub>44</sub>O<sub>3</sub>; 416.3290).

#### (5Z,7E)-9,10-Seco-cholesta-5,7,10(19)-trien-1β,3β,25-triol **NS8 5**

Provitamin **3** (150 mg, 0.36 mmol) was dissolved in methanol (100 mL), and *tert*-butyl methyl ether (350 mL) was added. The solution was transferred into a 450 mL photoreactor, and the photoreaction was carried out as described above. After 45 min of irradiation time, about 60% of **3** was consumed (TLC on Ag<sup>+</sup>-modified plates: ethyl acetate/hexane 75/25 v/v), the irradiation was stopped, and the solvent was evaporated under reduced pressure. The residue (yellowish oil) was dissolved in ethyl acetate/hexane and allowed to crystallize the unreacted **3** at  $-18^{\circ}$ C (48 mg, 32%). The mother liqour was separated by flash chromatography (Ag<sup>+</sup>-

modified silica gel, ethyl acetate/hexane 75/25 v/v). The following photoisomers were eluted in this order: previtamin (44 mg, 29.3%, colourless foam, UV (Ethanol):  $\lambda_{max} = 259$  nm), tachysterol (11 mg, 7.3%, colorless foam, UV (Ethanol):  $\lambda_{max} = 284$  nm), and unreacted **3** (8 mg, 5%). After irradiation recycling of **3** (56 mg), a total amount of 61 mg (40.7%) previtamin was obtained.

The corresponding tachysterol (10 mg in 40 mL tert-butyl methyl ether) was converted to the previtamin by sensitized photoisomerization using fluorenone (16 mg) as the sensitizer.<sup>20</sup> TLC and flash-chromomatographic separation of the reaction mixture as described above gave further previtamin (11 mg, 68.7% from tachysterol). Previtamin (70 mg) was dissolved in ethylacetate/ hexane (50 mL, 75/25 v/v) under argon and was heated to 60°C in the dark for 5 h (TLC on Ag<sup>+</sup>-modified plates: ethyl acetate/ hexane 75/25 v/v). The solvent was evaporated under reduced pressure, and the mixture was separated by flash-chromatography (Ag<sup>+</sup>-modified silica gel, ethyl acetate/hexane 75/25 v/v). After recycling of the unreacted previtamin (21 mg), a total amount of 56 mg 5 (37, 3% from 3) was obtained as white needles. m.p. 210–12°C. UV (C<sub>2</sub>H<sub>5</sub>OH)  $\lambda_{\text{max}} = 265 \text{ nm}$  ( $\epsilon = 16 600$ ). -<sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>):  $\delta$ : 0.53 (s, 3H, 18-H); 0.94 (d, <sup>3</sup>J  $\approx$ 6.4Hz, 3H, 21-H); 1.20 (s, 6H, 26-H and 27-H); 4.09 (m, 1H, 3 $\alpha$ -H), 4.34 (t, 1H, 1 $\alpha$ -H), 4.99 (d,  ${}^{4}J \approx$  1.9Hz, 1H, 19-H); 5.27 (s, 1H, 19-H), 6.03 and 6.45 (2 × d, AB pattern,  ${}^{3}J \approx 11.3$ Hz, 2H, 6-H and 7-H). Addition of trichloroacetyl isocyanate:  $\delta$ : 0.50 (s, 3H, 18-H); 0,90 (d,  ${}^{3}J \approx 6.4$ Hz, 3H, 21-H); 1.51 (s, 6H, 26-H and 27-H); 5.19 (s, 1H, 19-H); 5.20 (m, 1H, 3α-H); 5.48 (t, 1H, 1α-H); 5.51 (s, 1H, 19-H); 5.87 and 6.37 (d,  ${}^{3}J \approx 10.8$ Hz, 2H, 6-H and 7-H); 8.12, 8.59 and 8.69 ( $3 \times s$ ,  $3 \times 1H$ ,  $3 \times NH$ ). These physical data are in agreement with data in the literature.<sup>21</sup>

#### **Biological methods and materials**

#### Cell culture and transfection experiments

C3H10T<sup>1/2</sup> cells were obtained from the European Collection of Animal Cell Cultures (Porton Down) and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS, 2mM glutamine, 60 mg/L penicillin, and 100 mg/L streptomycin at 37°C under a humidified atmosphere (95% humidity) with 5% CO<sub>2</sub>. All cell culture flasks were precoated prior to cell culture for 1 h at 37°C with a solution of gelatin (10 mg/mL). The cell culture medium of the stably transfected cell lines C3H10T<sup>1</sup>/<sub>2</sub>(BMP-4) and C3H10T<sup>1</sup>/<sub>2</sub>(4xVDRE-CAT) were additionally supplemented with 5  $\mu$ g/mL puromycin during the entire cultivation period.

C3H10T<sup>1</sup>/<sub>2</sub>-cells stably transfected with the eukaryotic expression vector pMBC-2T-f1, containing the entire coding sequence of the human version of BMP-4, were used for the DNA-synthesis and the adipogenesis inhibition experiments. To create a vitamin D<sub>3</sub>-specific cellular gene activation test system, four direct repeats of the 32-base-pair DNA-fragment from the human osteocalcinvitamin D responsive element (osteocalcin-VDRE) with the sequence 5'-CTTGGTGACTCACCGGGTGAACGGGGGCA-TTA-3' were cloned into the BamH1 site of the chloramphenicolacetyltransferase(CAT)-expression vector pBLCAT2. The resulting expression vector pBLCAT2(4×VDRE) was stably transfected into C3H10T<sup>1</sup>/2-cells. Stable transfections were produced using the calcium-phosphate precipition method. Puromycin resistance of the stable transfectants was mediated by cotransfection with the plasmid pB Spac $\Delta p$ , which codes for the puromycin-acetyltransferase-gene.

#### Measurement of DNA synthesis

C3H10T<sup>1</sup>/<sub>2</sub>(BMP-4)-cells were precultured to near-confluence, diluted to 30,000 cells/mL, and transferred into 96-well plates. After cultivation to confluence, the culture medium was substituted with DMEM without FCS supplementation, and the cells were treated with  $10^{-13}$  M to  $10^{-5}$  M vitamin D<sub>3</sub> derivatives or solvent (ethanol). Five days later, the cells were labeled with 1  $\mu$ Ci/mL [methyl-<sup>3</sup>H]-thymidine (47 Ci/mmol). After 4.5 h of incubation and washing with PBS, 50  $\mu$ L of 0.4 M NaOH were added to each well, and each plate was sealed with a plate sealer sheet. The cells were lysed for 30 min at 80°C, and after the plates were cooled, 200  $\mu$ L of 2% perchloro acetic acid were added to each well. Following incubation for 2 h at 4°C, the radioactivity was harvested on glass fiber filters (XTalScint, Beckman) with a semiautomatic cell harvester (Bibby Dunn, 2800 Series). The radioactivity on each filter was counted in a Beckman LS 6000 IC scintillation counter. Six parallel experiments were conducted with each vitamin D derivative concentration.

#### Determination of CAT-activity

C3H10T<sup>1/2</sup>(4×VDRE)-cells were precultured to near-confluence, diluted to 30,000 cells/mL, and transferred into petri dishes (96 mm diameter) in DMEM containing 10% FCS. The cells were subsequently washed with PBS and further cultured in DMEM without FCS and in the presence of various amounts of vitamin D<sub>3</sub> derivative or solvent. The solvent concentration in the medium never exceeded 0.1%. After an incubation period of 60 h, the cells were washed three times with PBS. The washed cells were lysed, and the CAT-concentration of each sample was determined using a CAT-enzyme linked immunosorbent assay (ELISA) kit (Boehringer Mannheim).

#### Determination of the affinity of vitamin $D_3$ derivatives for the vitamin D receptor (VDR)

A  $1,25(OH)_2D_3$ -assay system (Amersham-Buchler, Braunschweig, Germany) was modified to determine the affinity of vitamin  $D_3$  derivatives for the VDR. Lyophilized intestinal VDR from rachitic chicken was reconstituted with 31 mL of 0.05 M potassium phosphate buffer, pH 7.4, containing 0.05 M potassium chloride, 1 mM dithiothreitol, and 0.1% (w/v) bovine  $\gamma$  globulin. VDR solution (500  $\mu$ L), 1,25-dihydroxy[26,27-methyl-<sup>3</sup>H]vitamin  $D_3$  (25  $\mu$ L, 0.5 ng/mL, 0.24  $\mu$ Ci/mL), and a sample of vitamin  $D_3$ 



Inhibition of proliferation.

Metabolite concentration (M)

**Figure 1** Inhibition of cell proliferation of C3H10T1/2(BMP-4)-cells by  $1,25(OH)_2D_3$ , 25(OH) $D_3$ , NS3 and NS8. C3H10T1/2(BMP-4)-cells were grown in 96-well plates and treated in serum-free medium with various concentrations of vitamin  $D_3$  derivatives or solvent (ethanol). Five days later the cells were labeled with 1  $\mu$ Ci/well [Methyl-<sup>3</sup>H]-thymidine (47 Ci/mmol) for 4.5 h, washed with PBS and lysed and [<sup>3</sup>H]-Thymidine incorporation was determined. †, 1,25(OH)<sub>2</sub> $D_3$ -induced cell lysis. Each point of the dose-response curve is the average of six wells. The results shown are representative of two to three experiments.

derivative (50  $\mu$ L) were combined and incubated for 1 h at 22°C. Immediately after this incubation period, free and bound vitamin D<sub>3</sub> were separated by adding 200  $\mu$ L of a dextran-coated charcoal suspension (0.5% w/v charcoal, 0.05% w/v dextran). Displacement of 1,25(OH)<sub>2</sub>D<sub>3</sub>-tracer from VDR by the vitamin D<sub>3</sub> derivatives was determined by assessing the radioactivity with a liquid scintillation counter.

## Determination of the affinity of vitamin $D_3$ derivatives for vitamin D binding protein (DBP)

A 25(OH)D<sub>3</sub>-assay system (Amersham-Buchler, Braunschweig, Germany) was modified to determine the affinity of vitamin D<sub>3</sub> derivatives for serum DBP. Lyophilized DBP from sheep serum was dissolved in 0.05 M potassium phosphate buffer, pH 7.4 containing 0.01% (w/v) bovine immunoglobulin G and 0.01% (w/v) thimerosol. Fifty  $\mu$ L 25(OH)[26,27-methyl-<sup>3</sup>H]vitamin D<sub>3</sub> (0.5 ng/mL, 0.19  $\mu$ Ci/mL) and 50  $\mu$ L of the vitamin D derivative sample were added to 500  $\mu$ L DPB solution, mixed, and incubated for 2 h at 4°C. Bound and free vitamin D<sub>3</sub> were separated by addition of 500  $\mu$ L dextran-coated charcoal suspension (0.275% w/v charcoal, 0.0275% w/v dextran) immediately after the incubation period. Displacement of the 25(OH)D<sub>3</sub>-tracer was measured with a liquid scintillation counter.

# Determination of adipocyte differentiation and cell number

C3H10T<sup>1</sup>/<sub>2</sub>(BMP-4)-cells were precultured to near-confluence, diluted to 30,000 cells/mL, and transferred into 12-well plates. After culturing to confluence, the culture medium was replaced with DMEM supplemented with 10% FCS, 50  $\mu$ g/mL ascorbate, and 10 mM  $\beta$ -glycerophosphate, and the cells were treated with  $10^{-13}$  M to  $10^{-5}$  M vitamin D<sub>3</sub> derivatives or solvent. Experiments were carried out in triplicate. Every 4-5 days, half of the media was replaced by fresh medium including the vitamin D<sub>3</sub> derivatives. After a culture period of 19 days, the cells were washed two times with PBS and 2 mL PBS per well were subsequently added. To each well, 20  $\mu$ L of a solution of 100  $\mu$ g/mL nile red in acetone were added. After an incubation period of 20 min at room temperature, the supernatant was discarded and 2 mL of PBS were added. The plates were scanned in a Cytofluor 2350 fluorescence photometer (excitation 485 nm/emission 530 nm) to determine the neutral lipid content of the cells. Subsequently, the cells were washed three times with PBS and fixed for 30 min with methanol, pH 8.5. Five hundred  $\mu$ L of a 0.1% (w/v) methylene blue solution in 10 mM borate buffer, pH 8.5, were added to each well. After 20 min, the cells were washed three times with 10 mM borate buffer, pH 8.5. For destaining, 4 mL of 0.1 M HCl containing 20% ethanol were added. After 20 min, the absorbance of the destaining solution was measured in a Multiskan photometer at 650 nm and correlated with a standard curve.

#### **Results**

The actions of  $1,25(OH)_2D_3$ ,  $25(OH)D_3$ , **NS3**, and **NS8** on the murine fibroblastic cell line C3H10T<sup>1/2</sup> were examined over a concentration range of  $10^{-5}-10^{-13}$  M. The biologically active vitamin D<sub>3</sub> metabolite  $1,25(OH)_2D_3$  was the best inhibitor of proliferation of C3H10T<sup>1/2</sup>(BMP-4)-cells of all tested vitamin D<sub>3</sub> derivatives. Even at the low dose of  $10^{-11}$  M inhibition of proliferation exceeds 50% (Figure 1). All other examined vitamin D<sub>3</sub> derivatives were significantly weaker. **NS3** and 25(OH)D<sub>3</sub> inhibited proliferation of C3H10T<sup>1/2</sup>(BMP-4)-cells in quite a similar way. In contrast to  $1,25(OH)_2D_3$ , **NS3** and  $25(OH)D_3$  showed only a significant inhibitory effect at concentrations above  $10^{-8}$  M. **NS8** was the best proliferation-inhibitor of the A-ring derivatives of  $1,25(OH)_2D_3$  with 30% inhibition at  $10^{-10}$  M.

The most significant differences between  $1,25(OH)_2D_3$ and the synthetic vitamin  $D_3$  derivatives were their gene activating properties at the VDRE-CAT-construct.  $1,25(OH)_2D_3$  induces the CAT-gene seventeen-fold at a concentration as low as  $10^{-11}$  M (Figure 2). The gene activating activities of **NS3** and  $25(OH)D_3$  were nearly 10,000 times weaker. Both derivatives had a similar effect at all tested concentrations. **NS8** was slightly more active than NS3 and  $25(OH)D_3$  with nearly three times higher CAT-activity at  $10^{-8}$  M.

The 1 $\beta$ -derivatives displayed a weak affinity for the VDR similar to that of the 1,25(OH)<sub>2</sub>D<sub>3</sub>-precursor 25(OH)D<sub>3</sub>, which is about 20,000 times weaker than the VDR affinity of 1,25(OH)<sub>2</sub>D<sub>3</sub> (Figure 3). As shown by the 50% displacement of **NS8** at a concentration of 9 × 10<sup>-7</sup> M, this metabolite has nearly two times higher VDR affinity than 25(OH)D<sub>3</sub>. The affinity of the 2 $\alpha$ -chlor-derivative of **NS8**, **NS3**, was nearly ten times lower.

**NS3** and **NS8** showed major differences in DBP affinity. At a concentration of  $2 \times 10^{-7}$  M, **NS3** displaced 50% of the 25(OH)D<sub>3</sub>-tracer (Figure 4). **NS8** had a 50% displacement concentration of  $9 \times 10^{-9}$  M, which is nearly 22 times lower than that of **NS3** and only nearly six times higher than that of 25(OH)D<sub>3</sub>, the main transportable form of vitamin D<sub>3</sub> in the blood. At concentrations of **NS8** below  $10^{-8}$  M, the DBP binding curve in the competition experiment differed significantly from the ideal sigmoidal form. At these low concentrations, **NS8** showed an even higher affinity for DBP than 25(OH)D<sub>3</sub>.

In contrast to all other tested substances,  $1,25(OH)_2D_3$ displayed a strong inhibitory effect on adipocyte differentiation. At all but the lowest concentration tested,  $1,25(OH)_2D_3$  diminished the neutral lipid concentration of C3H10T<sup>1/2</sup>(BMP-4)-cells to 20% of control. Even at a concentration of  $10^{-13}$  M, the fat concentration barely exceeded the 60% mark. The microscopic control of cell morphology confirmed the fluorescence measurement because of the virtual absence of preadipocyte-like, fat droplets-containing, rounded cells at all concentrations with low fluorescence. The main reason for the inhibition of adipocyte differentiation is the proliferation-inhibitory activity of  $1,25(OH)_2D_3$ . Its ID<sub>50</sub> concentration was about ten times higher compared to its inhibition of proliferation in serum-free cell culture. The other three tested derivatives were weak inhibitors of adipocyte differentiation and cell proliferation at concentrations above  $10^{-7}$  M. The significantly stronger proliferation-inhibitory effect of NS8 on C3H10T<sup>1</sup>/<sub>2</sub>-cells in serum-free culture compared to both  $25(OH)D_3$  and NS3 was not seen in the presence of FCS. Inhibition of adipogenesis and inhibition of cell proliferation of these three derivatives seems to be tightly coupled under these conditions.

#### Discussion

We examined the in vitro biological activities of  $1,25(OH)_2D_3$ , 25(OH)D3, and two  $1\beta$ -derivatives on

#### **CAT-expression**



Metabolite concentration (M)

**Figure 2** Dependence of CAT-production in C3H10T1/2(4xVDRE-CAT) cells on  $1,25(OH)_2D_3$ ,  $25(OH)D_3$ , NS3 and NS8. Stable transfected C3H10T1/2 cells with chloramphenicol-acetyltransferase expression vector pBLCAT2 containing four direct repeats of the human osteocalcin VDRE were grown in 96 well plates and treated in serum-free medium with various concentrations of vitamin  $D_3$  derivatives or solvent (ethanol) for 60 h. After washing the cells were lysed and the CAT concentration was determined using a CAT enzyme linked immunosorbent assay kit. †,  $1,25(OH)_2D_3$ -induced cell lysis. The experiments were carried out in triplicates. The results shown are representative of two to three experiments.

C3H10T<sup>1</sup>/<sub>2</sub>-cells and their binding affinities for VDR and DBP. We tested the inhibition of cell proliferation and the gene-activating activity of these seco-steroids in the absence of FCS. Therefore, it was possible to separate DBP-coupled processes from their direct cellular activities. The C3H10T<sup>1</sup>/<sub>2</sub>(BMP-4)-cells are highly sensitive for the native, biologically active vitamin  $D_3$  metabolite 1,25(OH)<sub>2</sub> $D_3$ : proliferation-inhibitory activity was clearly detectable at concentrations as low as  $10^{-11}$  M. The same concentration was also sufficient to activate a VDRE-CAT-construct in C3H10T<sup>1</sup>/<sub>2</sub>(4×VDRE-CAT)-cells nearly 18-fold relative to the control. However, in the presence of FCS, a nearly ten times higher concentration of 1,25(OH)<sub>2</sub>D<sub>3</sub> was needed to reach half-maximal inhibition of cell proliferation due to the presence of DBP and lipoprotein in FCS to which binds a significant amount of  $1,25(OH)_2D_3$ . The effect of  $1,25(OH)_2D_3$  on cell proliferation in the absence as well as in the presence of FCS was strictly dose dependent. Although mainly dependent on the strong proliferationinhibitory activity of 1,25(OH)<sub>2</sub>D<sub>3</sub>, the inhibitory effect of  $1,25(OH)_2D_3$  on adipocyte differentiation seems to be regulated by an "on or off" mechanism. Further experiments with a lower concentration range are needed to elucidate the

putative independency of adipocyte differentiation and inhibition of proliferation induced by  $1,25(OH)_2D_3$ .

The two examined 1 $\beta$ -derivatives of 1,25(OH)<sub>2</sub>D<sub>2</sub>, NS3 and NS8, both displayed a low affinity for VDR in the range of the weakly active 1,25(OH)<sub>2</sub>D<sub>3</sub>-precursor 25(OH)D<sub>3</sub>. **NS8** showed a slightly higher VDR-affinity than 25(OH)D<sub>3</sub>, whereas NS3 bound with the lowest affinity of all tested substances. This explains the low proliferation-inhibitory and CAT-activating activities of NS3. In both experiments, a concentration of more than  $10^{-8}$  M was needed to see a significant effect. The slightly higher VDR-affinity of NS8 compared to that of NS3 led to a somewhat higher CATactivity. However, the greater than hundred fold higher inhibition of cell proliferation is not fully explained by the VDR-affinity of NS8. Since the VDR-affinity of NS8 is congruent with its CAT-activity and because geneactivating and cell proliferation experiments were both carried out in C3H10T<sup>1</sup>/2-cells,<sup>22</sup> different catabolic or "steroid-sorting" processes by membrane transporters during inhibition of cell proliferation are unlikely. One possibility is that the VDR needs a different dimerization partner for inhibition of cell proliferation than for VDRE-CAT activation. Since ligand binding and heterodimerization of



Figure 3 Displacement of [<sup>3</sup>H]-1,25(OH)<sub>2</sub>D<sub>3</sub> from chicken intestine vitamin D receptor by increasing concentrations of 1,25(OH)<sub>2</sub>D<sub>3</sub>, 25(OH)D<sub>3</sub>, NS3 and NS8. An 1,25(OH)<sub>2</sub>D<sub>3</sub> assay system was used to determine the affinity of vitamin D<sub>3</sub> derivatives to VDR. Intestinal VDR from rachitic chicken was incubated with 1,25-dihydroxy[26,27methyl-<sup>3</sup>H] vitamin D<sub>3</sub> and increasing concentrations of vitamin D<sub>2</sub> derivatives for 1 h at 22°C. Bound and free [<sup>3</sup>H]-1,25(OH)<sub>2</sub>D<sub>3</sub> were separated by the addition of dextran coated charcoal suspension. Displacement of [3H]1,25(OH),D, was measured in a liquid scintillation counter. Experiments were carried out in duplicates.

members of the steroid hormone receptor superfamily are tightly coupled processes, the binding of **NS8** possibly favors the heterodimerization and subsequent transactivation events needed for effective inhibition of cell proliferation. **NS8** could be a vitamin  $D_3$  derivative which shows a dissociation of the multiple vitamin  $D_3$  effects at a transcriptional level.

All three derivatives display only weak effects on adipocyte differentiation (Figure 5) because of the high DBPaffinities and low VDR-affinities of 25(OH)D3 and **NS8**, and the extremely weak VDR-affinity of **NS3**.

The dose-response relationships of DBP-binding of the 1*B*-derivatives NS3 and NS8 differ significantly from each other. Bishop et al. have previously found that NS8 has a higher affinity for DBP than 1,25(OH)<sub>2</sub>D<sub>3</sub>.<sup>23</sup> In Figure 4, NS8 does not show the sigmoidal binding curve typical for equilibrium binding experiments. The higher affinity of **NS8** compared to that of  $25(OH)D_3$  for DBP in the low concentration range between  $10^{-10}$  M and  $10^{-9}$  M could only be explained by the existence of more than one population of binding sites on DBP.24 At least one population of binding sites seems to have a higher affinity for NS8 than for 25(OH)D<sub>3</sub>. A  $2\alpha$ -chloro substituent led back to a sigmoidal monophasic binding curve as shown by NS3. This derivative seemed to have lost the ability to bind to high affinity binding site population(s) typical for NS8 binding and had a lower affinity for the 25(OH)D<sub>3</sub>-specific binding site than 25(OH)D<sub>3</sub>. A possible explanation for this surprisingly different behavior could be differences in the A-ring conformation of these two A-ring derivatives of vitamin D<sub>3</sub>. The  $2\alpha$ -chloro substituent and the  $1\beta$ - and  $3\beta$ -hydroxy functions in NS3 stabilize a conformation with the three substituents in the equatorial position. Therefore, the whole





**Figure 4** Displacement of [<sup>3</sup>H]-25(OH)D<sub>3</sub> from sheep serum vitamin D binding protein by increasing concentrations of 1,25(OH)<sub>2</sub>D<sub>3</sub>, 25(OH)D<sub>3</sub>, NS3 and NS8. A 25 (OH)D<sub>3</sub> assay system was used to determine the affinity of vitamin D<sub>3</sub> derivatives to serum DBP. DBP from sheep serum were incubated with 25(OH)[26,27-methyl-<sup>3</sup>H] vitamin D<sub>3</sub> and increasing concentrations of vitamin D<sub>3</sub> derivatives for 2 h at 4°C. Bound and free [<sup>3</sup>H]-25(OH)D<sub>3</sub> were separated by the addition of dextran coated charcoal suspension. Displacement of [<sup>3</sup>H]-25(OH)D<sub>3</sub> was measured in a liquid scintillation counter. Experiments were carried out in duplicates.



Interrelation of adipocyte differentiation and inhibition of proliferation.

**Figure 5** Interrelation of adipocyte differentiation and inhibition of cell proliferation of C3H10T1/2(BMP-4)-cells by 1,25(OH)<sub>2</sub>D<sub>3</sub>, 25(OH)D<sub>3</sub>, NS3 and NS8. C3H10T1/2(BMP-4)-cells were cultured to confluence in 12-well plates. At confluence, the medium was replaced with DMEM supplemented with 10% FCS, 50  $\mu$ g/mL ascorbate, and 10 mM  $\beta$ -glycerophosphate and treated with vitamin D<sub>3</sub> derivatives or solvent. Every 4–5 days, halve of the medium was replaced with fresh medium including the vitamin D<sub>3</sub> derivatives. After a culture period of 19 days, the cells were washed and after addition of nile red and washing, the neutral lipid content was determined in a Cytofluor 2350 fluorescence photometer (excitation 485 nm/emission 530 nm). Subsequently the cells were fixed in methanol treated with methylene blue solution for 20 min. After washing and lysis of the cells the absorbance was measured in a multiscan photometer at 650 nm and correlated with a standard curve. †, 1,25(OH)<sub>2</sub>D<sub>3</sub>-induced cell lysis. Experiments were carried out in triplicates. The results shown are representative of two to three experiments.

A-ring is fixed in one of the two chair conformations. This seems to be unfavorable for at least one population of binding sites for which **NS8** has higher affinity than  $25(OH)D_3$ . Both chair conformations in **NS8** are, in contrast to **NS3**, energetically possible. However, it is unclear which specific A-ring conformation is favored for binding to the postulated population of high and low affinity binding sites and which other structural elements of the ligand are important for optimal binding.<sup>25</sup>

The in vitro biological effects of the examined  $1\beta$ vitamin D<sub>3</sub> derivatives are, as expected from the VDR binding data, weak compared to those of  $1,25(OH)_2D_3$ . However, a closer examination of the heterodimerization properties of the VDR in the presence of **NS8** and the unusually high affinity binding of **NS8** to new binding site(s) on the DBP, especially at low metabolite concentrations, could be interesting for the modulation of specific transcriptional activities and of pharmacokinetical characteristics of other highly biologically active vitamin D<sub>3</sub> derivatives.

#### Acknowledgments

Financial support of this work by the Deutsche Forschungsgemeinschaft (Scho 488/1-1, Scho 488/1-2, Ma 852/6-1, Scho 488/1-3, Ma 852/6-2) and by the Schering AG (B.S.) is gratefully acknowledged. We thank G. Gross for providing the BMP cells.

#### References

- Itin PH, Pittelkow MR, Kumar R (1994). Effects of vitamin D metabolites on proliferation and differentiation of cultured human epidermal keratinocytes grown in serum-free or defined culture medium. *Endocrinology* 135:1793–1798.
- 2. Franceschi RT, James WM, Zerlauth G (1985).  $1\alpha$ ,25dihydroxyvitamin D<sub>3</sub> regulation of growth, morphology, and fibronectin in a human osteosarcoma cell line. *J Cell Phys* **123**:401– 409.
- Clohisy DR, Bar-Shavit Z, Chappel JC, Teitelbaum SL (1987). 1,25-dihydroxy-vitamin D<sub>3</sub> modulates bone marrow macrophage precursor proliferation and differentiation. *J Biol Chem* 262:15922– 15929.
- Thavarajah M, Evans DB, Kanis JA (1991). 1,25(OH)<sub>2</sub>D<sub>3</sub> induces differentiation of osteoclast-like cells from human bone marrow cultures. *Biochem Biophys Res Commun* 176:1189–1195.
- Mathieu C, Waer M, Casteels K, Laureys J, Bouillon R (1995). Prevention of Type 1 diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D<sub>3</sub>, KH 1060. *Endocrinology* 136:866–872.
- Okamura WH, Palenzuela JA, Plumet J, Midland MM (1992). Vitamin D: structure-function analyses and the design of analogs. *J Cell Biochem* 49:10–18.
- Binderup L, Bramm E (1988). Effects of a novel vitamin D analogue MC 903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. *Biochem Pharm* 37:889–895.

#### Papers

- Norman AW, Nemere I, Muralidharan KR, Okamura WH (1992). 1β,25(OH)<sub>2</sub>-vitamin D<sub>3</sub> stimulated transcaltachia (the rapid hormonal stimulation of intestinal calcium transport). *Biochem Biophys Res Commun* 189:1450–1456.
- Posner GH, Cho C-G, Anjeh TEN, Johnson N, Horst RL, Kobayashi T, Okano T, Tsugawa N (1995). 2-Fluoroalkyl A-ring analogs of 1,25-dihydroxyvitamin D<sub>3</sub>. Stereocontrolled total synthesis via intramolecular and intermolecular Diels–Alder cycloadditions. Preliminary biological testing. *J Org Chem* 60:4617–4628.
- Ahrens M, Ankenbauer T, Schröder D, Hollnagel A, Mayer H, Gross G (1993). Expression of human bone morphogenetic proteins-2 or -4 in murine mesenchymal progenitor C3H10T<sup>1</sup>/<sub>2</sub> cells induced differentiation into distinct mesenchymal cell lineages. DNA Cell Biol 12:871–880.
- Scheddin D, Mayer H, Wittmann S, Schönecker B, Gliesing S, Reichenbächer M (1996). Synthesis and biological activities of 26-hydroxy-27-nor-derivatives of 1α,25-dihydroxyvitamin D<sub>3</sub>. Steroids 61:598–608.
- 12. Wittmann S, Krieg R, Prousa R, Schönecker B, Droescher P (1996). Transformation of (20S)-20-(hydroxymethyl)pregna-1,4-dien-3-one into (20S)-20-(p-toluenesulfonyloxymethyl)pregna-1,4-dien-3 $\beta$ -ol and -3 $\alpha$ -ol, intermediates of vitamin D derivatives. *J Prakt Chem* **338**:214–219.
- Schönecker B, Prousa R, Reichenbächer M, Gliesing S, Kosan H, Droescher P, Hauschild U, Thieroff-Ekerdt R (1993). Synthesis of 3β-acetoxy-1β,2β-epoxy-25-hydroxy-cholesta-5,7-diene and 2β,25dihydroxyvitamin D<sub>3</sub>. *Bioorg Med Chem Lett* **3**:1849–1854.
- Schönecker B, Droescher P, Adam G, Marquardt V, Walther D, Fischer R, Prousa R (1992). Ausgangsverbindungen zur Herstellung von Calcitriol sowie dessen Abkömmlingen, Verfahren zur Herstellung dieser Ausgangsverbindungen sowie Zwischenprodukte für dieses Verfahren. PCT/DE 92/00128. Chem Abstr (1993) 118:124879.
- Reichenbächer M, Gliesing S, Lange C, Gonschior M, Schönecker B (1996). Ein effektives Verfahren zur Herstellung von 1α,25-

Dihydroxy-cholecalciferol (Calcitriol) aus  $1\alpha$ , $3\beta$ ,25-Trihydroxy-cholesta-5,7-dien (Procalcitriol). *J Prakt Chem* **338**:634–641.

- Reichenbächer M, Gliesing S, Hopf G (1991). Eine verbesserte Apparatur f
  ür die Flash-Chromatographie. J Prakt Chem 333:779– 784.
- Ponsold K (1963). Stickstoffhaltige Steroide, IV: Darstellung von Azidohydrinen und vicinalen Aminoalkoholen aus Epoxysterinen. *Chem Ber* 96:1855–1864.
- Glotter E, Krinsky P (1978). Neighbouring group effects in the acid-catalysed opening of steroidal epoxides. J Chem Soc Perkin Trans 1 413–419.
- Oshima E, Sai H, Takatsuto S, Ikekawa N, Kobayashi Y, Tanaka Y, DeLuca HF (1984). Synthesis and biological activity of 1α-fluoro-25-hydroxyvitamin D<sub>3</sub>. *Chem Pharm Bull (Tokyo)* 32:3525–3531.
- Eyley SC, Williams DH (1975). Photolytic productions of vitamin D. The preparative value of a photo-sensitizer. J Chem Soc, Chem Commun 858.
- Muralidharan KR, de Lera AR, Isaeff SD, Norman AW, Okamura WH (1993). Studies on the A-ring diastereomers of 1α,25dihydroxyvitamin D<sub>3</sub>. J Org Chem 58:1895–1899.
- 22. Thompson EB (1995). Membrane transporters of steroid hormones. *Curr Biol* **5**:730–732.
- Bishop JE, Collins DE, Okamura WH, Norman AW (1994). Profile of ligand specificity of the vitamin D binding protein for 1α,25dihydroxyvitamin D<sub>3</sub> and its analogs. *J Bone Min Res* 9:1277–1288.
- Hulme EC, Birdsall NJM (1992). Strategy and tactics in receptorbinding studies. In: Hulme EC (ed), *Receptor-Ligand Interactions: A Practical Approach*. IRL Press, Oxford, New York, Tokyo, pp. 63–176.
- Okamura WH, Midland MM, Hammond MW, Rahman NA, Dormanen MC, Nemere I, Norman AW (1994). Conformation and related topological features of Vitamin D: structure-function relationships In: Norman AW, Bouillon R, Thomasset M (eds), Vitamin D, a Pluripotent Steroid Hormone: Structural, Molecular Endocrinology and Clinical Applications. Walter de Gruyter, Berlin, New York, pp. 12–19.